3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Pancreatic Ductal
1
Adenocarcinoma
1
Interventions
Gemcitabine
3
ensituximab
1
Lead
1
Immunotherapy, Adoptive
1
Cetuximab
1
Bevacizumab
1
Atu027
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Carcinoma, Pancreatic Ductal
×
Atu027
×
Clear all
NCT01808638
2016-03-11
Atu027-I-02
Silence Therapeutics GmbH
Phase 1/2
Completed
29 enrolled